Law firm Kahn Swick & Foti, LLC has announced a securities fraud class action lawsuit against Corcept Therapeutics Incorporated, alleging the company failed to disclose material information regarding its relacorilant drug candidate. The pharmaceutical firm's stock declined 50.4% following the FDA's issuance of a Complete Response Letter, which effectively halted the anticipated approval pathway for the treatment candidate.
The lawsuit represents one of several securities actions filed by the firm targeting companies that experienced significant stock declines tied to regulatory and operational setbacks. Similar cases have been brought against uniQure N.V., which saw its stock fall 49% following FDA approval delays, and BellRing Brands, which experienced a 52% decline amid inventory management issues. These concurrent filings suggest a pattern of alleged disclosure failures across the sector during a period of heightened regulatory scrutiny.
Investors who held Corcept Therapeutics securities during the relevant period have until April 21, 2026 to submit lead plaintiff applications in the ongoing litigation. The case will proceed through discovery to determine whether company officials had prior knowledge of the FDA's concerns regarding relacorilant and failed to inform shareholders of material risks.